Title:
COMPOSITIONS AND METHODS FOR PREDICTION OF DRUG SENSITIVITY, RESISTANCE, AND DISEASE PROGRESSION
Document Type and Number:
WIPO Patent Application WO/2011/133477
Kind Code:
A3
Abstract:
The present invention is based on the discovery that functional stratification and/or signaling profiles can be used for diagnosing disease status, determining drug resistance or sensitivity of cancer cells, monitoring a disease or responsiveness to a therapeutic agent, and/or predicting a therapeutic outcome for a subject. Provided herein are assays for diagnosis and/or prognosis of diseases in patients. Also provided are compositions and methods that evaluate the resistance or sensitivity of diseases to targeted therapeutic agents prior to initiation of the therapeutic regimen and to monitor the therapeutic effects of the therapeutic regimen. Also provided are methods for determining the difference between a basal level or state of a molecule in a sample and the level or state of the molecule after stimulation of a portion of the live sample with a modulator ex vivo, wherein the difference is expressed as a value which is indicative of the presence, absence or risk of having a disease. The methods of the invention may also be used for predicting the effect of an agent on the disease and monitoring the course of a subject's therapy.
Inventors:
CLARK DOUGLAS P (US)
SCHAYOWITZ ADAM (US)
CABRADILLA CIRILO (US)
SCHAYOWITZ ADAM (US)
CABRADILLA CIRILO (US)
Application Number:
PCT/US2011/032935
Publication Date:
May 10, 2012
Filing Date:
April 18, 2011
Export Citation:
Assignee:
BIOMARKER STRATEGIES LLC (US)
CLARK DOUGLAS P (US)
SCHAYOWITZ ADAM (US)
CABRADILLA CIRILO (US)
CLARK DOUGLAS P (US)
SCHAYOWITZ ADAM (US)
CABRADILLA CIRILO (US)
International Classes:
G01N33/68; C12Q1/68; G01N33/15; G01N33/53; G16B5/00; G16B20/20
Foreign References:
| US6218122B1 | 2001-04-17 |
Other References:
JIMENO, A. ET AL.: "Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.", ONCOGENE, vol. 28, no. 4, 2009, pages 610 - 618
HARTZ, A. M. S. ET AL.: "17-beta-esradiol: a powerful modulator of blood-brain barrier BCRP activity.", J. CEREB. BLOOD FLOW METAB., vol. 30, 10 March 2010 (2010-03-10), pages 1742 - 1755
HUARTE, E. ET AL.: "PILAR is a novel modulator of human T-cell expansion.", BLOOD, vol. 112, no. 4, 15 August 2008 (2008-08-15), pages 1259 - 1268, XP002547878
HARTZ, A. M. S. ET AL.: "17-beta-esradiol: a powerful modulator of blood-brain barrier BCRP activity.", J. CEREB. BLOOD FLOW METAB., vol. 30, 10 March 2010 (2010-03-10), pages 1742 - 1755
HUARTE, E. ET AL.: "PILAR is a novel modulator of human T-cell expansion.", BLOOD, vol. 112, no. 4, 15 August 2008 (2008-08-15), pages 1259 - 1268, XP002547878
Attorney, Agent or Firm:
HAILE, Lisa, A. (4365 Executive Drive Suite 110, San Diego CA, US)
Download PDF: